

## Washington State Health Care Authority Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

https://www.hca.wa.gov/about-hca/prescription-drug-program

April 3, 2020

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective April 1, 2020:

| MS Drugs reviewed 8/15/2018 |  | Agency Coverage |     |
|-----------------------------|--|-----------------|-----|
| Ingredient Name             | <b>Label Name of Preferred Product</b> | L&I             | UMP |
| dimethyl fumarate           | Tecfidera <sup>®</sup> capsule         | No              | Yes |
|                             | Tecfidera Starter Pack®                | No              | Yes |
| fingolimod HCL              | Gilenya <sup>®</sup> capsule           | No              | Yes |
| glatiramer acetate          | glatiramer acetate syringe             | No              | Yes |
|                             | Glatopa <sup>®</sup> syringe           | No              | Yes |
| interferon beta-1A          | Avonex <sup>®</sup> kit                | No              | Yes |
|                             | Avonex Pen® kit                        | No              | Yes |

The effect of this recommendation is to make Copaxone and Betaseron non-preferred on the WA PDL.

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our website.

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at <a href="mailto:leta.evaskus@hca.wa.gov">leta.evaskus@hca.wa.gov</a>.

Sincerely,

Donna Sullivan

Chief Pharmacy Officer

MUAL Sillen.

Clinical Quality and Care Transformation

Washington State Health Care Authority